Sara Nik
Stock Analyst at H.C. Wainwright
(0.11)
# 4,658
Out of 4,712 analysts
54
Total ratings
20%
Success rate
-19.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBRX Moleculin Biotech | Reiterated: Buy | $22 → $3 | $0.765 | +292.16% | 18 | Aug 28, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 14.00 → kr 12.00 | kr 1.69 | +610.06% | 10 | Aug 21, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $9 | $1.85 | +386.49% | 5 | Aug 21, 2026 | |
| CRIS Curis | Reiterated: Buy | $43 | $1.20 | +3,483.33% | 10 | Aug 17, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.5697 | +426.59% | 10 | Aug 17, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $1.66 | n/a | 1 | Aug 13, 2025 |
Moleculin Biotech
Aug 28, 2026
Reiterated: Buy
Price Target: $22 → $3
Current: $0.765
Upside: +292.16%
Cantargia AB (publ)
Aug 21, 2026
Reiterated: Buy
Price Target: kr 14.00 → kr 12.00
Current: kr 1.69
Upside: +610.06%
Tvardi Therapeutics
Aug 21, 2026
Reiterated: Buy
Price Target: $9
Current: $1.85
Upside: +386.49%
Curis
Aug 17, 2026
Reiterated: Buy
Price Target: $43
Current: $1.20
Upside: +3,483.33%
Pasithea Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $3
Current: $0.5697
Upside: +426.59%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $1.66
Upside: n/a